Role of omalizumab in refractory chronic spontaneous urticaria: A single referral center experience
Background: Multiple evidence have shown that omalizumab, a subcutaneous (SC) anti-IgE monoclonal antibody, is highly effective for the treatment of chronic spontaneous urticaria (CSU). Objective: The objective is to evaluate the safety and efficacy of omalizumab administered 300 mg SC 1st month fol...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
Series: | Indian Journal of Drugs in Dermatology |
Subjects: | |
Online Access: | http://www.ijdd.in/article.asp?issn=2455-3972;year=2018;volume=4;issue=1;spage=18;epage=22;aulast=Singh |
id |
doaj-b8c2b253980b4e1a9b4322425be8b202 |
---|---|
record_format |
Article |
spelling |
doaj-b8c2b253980b4e1a9b4322425be8b2022020-11-25T00:30:55ZengWolters Kluwer Medknow PublicationsIndian Journal of Drugs in Dermatology2455-39722455-39722018-01-0141182210.4103/ijdd.ijdd_2_18Role of omalizumab in refractory chronic spontaneous urticaria: A single referral center experienceGautam Kumar SinghManas ChatterjeeRajesh VermaBackground: Multiple evidence have shown that omalizumab, a subcutaneous (SC) anti-IgE monoclonal antibody, is highly effective for the treatment of chronic spontaneous urticaria (CSU). Objective: The objective is to evaluate the safety and efficacy of omalizumab administered 300 mg SC 1st month followed by 150 mg every month for another 5 months in cases of refractory CSU in a routine clinical setting. Materials and Methods: This was open-label, prospective, pilot study to know the efficacy and safety profile of omalizumab administered 300 mg SC first 1st month followed by 150 mg every month for another five 5 months in refractory CSU. The study was conducted at tertiary center in routine clinical setting. The primary efficacy evaluation was a change in Urticaria Activity Score-7 (UAS-7) and Urticaria Control Test (UCT) from baseline. Results: A total of 13 patients (7 females and 6 males) were enrolled in the study with the mean age of 35 years, having CSU from the mean duration of 3.15 years. Mean UAS-7 of patients decreased from 31.62 at baseline to 6.85 after the first dose of omalizumab treatment. This further reduced to 2.31 after 6 months (P = 0.001). Mean UCT increased from 4.46 at baseline to 13.92 after 1 month and further increased to 14.85 after 6 months (P = 0.001). A total of 11 patients (84.6%) achieved complete remission. Conclusion: Injection omalizumab is safe and highly effective therapy for refractory CSU in the routine clinical setting. It can be made cost effective without compromising the efficacy in resource-poor country of Indian subcontinent if barring first dose other can be halved of recommended dose. However, small number of patients, uncontrolled study and lack of long-term follow-up data are the limitations of the study.http://www.ijdd.in/article.asp?issn=2455-3972;year=2018;volume=4;issue=1;spage=18;epage=22;aulast=SinghChronic spontaneous urticariaomalizumaburticaria activity score 7urticaria control test |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gautam Kumar Singh Manas Chatterjee Rajesh Verma |
spellingShingle |
Gautam Kumar Singh Manas Chatterjee Rajesh Verma Role of omalizumab in refractory chronic spontaneous urticaria: A single referral center experience Indian Journal of Drugs in Dermatology Chronic spontaneous urticaria omalizumab urticaria activity score 7 urticaria control test |
author_facet |
Gautam Kumar Singh Manas Chatterjee Rajesh Verma |
author_sort |
Gautam Kumar Singh |
title |
Role of omalizumab in refractory chronic spontaneous urticaria: A single referral center experience |
title_short |
Role of omalizumab in refractory chronic spontaneous urticaria: A single referral center experience |
title_full |
Role of omalizumab in refractory chronic spontaneous urticaria: A single referral center experience |
title_fullStr |
Role of omalizumab in refractory chronic spontaneous urticaria: A single referral center experience |
title_full_unstemmed |
Role of omalizumab in refractory chronic spontaneous urticaria: A single referral center experience |
title_sort |
role of omalizumab in refractory chronic spontaneous urticaria: a single referral center experience |
publisher |
Wolters Kluwer Medknow Publications |
series |
Indian Journal of Drugs in Dermatology |
issn |
2455-3972 2455-3972 |
publishDate |
2018-01-01 |
description |
Background: Multiple evidence have shown that omalizumab, a subcutaneous (SC) anti-IgE monoclonal antibody, is highly effective for the treatment of chronic spontaneous urticaria (CSU). Objective: The objective is to evaluate the safety and efficacy of omalizumab administered 300 mg SC 1st month followed by 150 mg every month for another 5 months in cases of refractory CSU in a routine clinical setting. Materials and Methods: This was open-label, prospective, pilot study to know the efficacy and safety profile of omalizumab administered 300 mg SC first 1st month followed by 150 mg every month for another five 5 months in refractory CSU. The study was conducted at tertiary center in routine clinical setting. The primary efficacy evaluation was a change in Urticaria Activity Score-7 (UAS-7) and Urticaria Control Test (UCT) from baseline. Results: A total of 13 patients (7 females and 6 males) were enrolled in the study with the mean age of 35 years, having CSU from the mean duration of 3.15 years. Mean UAS-7 of patients decreased from 31.62 at baseline to 6.85 after the first dose of omalizumab treatment. This further reduced to 2.31 after 6 months (P = 0.001). Mean UCT increased from 4.46 at baseline to 13.92 after 1 month and further increased to 14.85 after 6 months (P = 0.001). A total of 11 patients (84.6%) achieved complete remission. Conclusion: Injection omalizumab is safe and highly effective therapy for refractory CSU in the routine clinical setting. It can be made cost effective without compromising the efficacy in resource-poor country of Indian subcontinent if barring first dose other can be halved of recommended dose. However, small number of patients, uncontrolled study and lack of long-term follow-up data are the limitations of the study. |
topic |
Chronic spontaneous urticaria omalizumab urticaria activity score 7 urticaria control test |
url |
http://www.ijdd.in/article.asp?issn=2455-3972;year=2018;volume=4;issue=1;spage=18;epage=22;aulast=Singh |
work_keys_str_mv |
AT gautamkumarsingh roleofomalizumabinrefractorychronicspontaneousurticariaasinglereferralcenterexperience AT manaschatterjee roleofomalizumabinrefractorychronicspontaneousurticariaasinglereferralcenterexperience AT rajeshverma roleofomalizumabinrefractorychronicspontaneousurticariaasinglereferralcenterexperience |
_version_ |
1725324926539268096 |